Vanguard Group Inc. Boosts Stock Holdings in Cellectar Biosciences, Inc. (NASDAQ:CLRB)

Vanguard Group Inc. grew its position in shares of Cellectar Biosciences, Inc. (NASDAQ:CLRB) by 2.3% during the third quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The fund owned 175,884 shares of the biopharmaceutical company’s stock after buying an additional 3,911 shares during the quarter. Vanguard Group Inc. owned 1.43% of Cellectar Biosciences worth $464,000 as of its most recent filing with the Securities & Exchange Commission.

A number of other institutional investors have also recently made changes to their positions in CLRB. Worth Venture Partners LLC grew its holdings in shares of Cellectar Biosciences by 122.8% during the first quarter. Worth Venture Partners LLC now owns 458,245 shares of the biopharmaceutical company’s stock valued at $315,000 after buying an additional 252,570 shares during the last quarter. Renaissance Technologies LLC grew its holdings in shares of Cellectar Biosciences by 31.3% during the second quarter. Renaissance Technologies LLC now owns 166,500 shares of the biopharmaceutical company’s stock valued at $67,000 after buying an additional 39,700 shares during the last quarter. State Street Corp grew its holdings in shares of Cellectar Biosciences by 4.5% during the second quarter. State Street Corp now owns 157,146 shares of the biopharmaceutical company’s stock valued at $63,000 after buying an additional 6,800 shares during the last quarter. Citadel Advisors LLC purchased a new stake in Cellectar Biosciences in the second quarter worth approximately $60,000. Finally, Acuta Capital Partners LLC purchased a new stake in Cellectar Biosciences in the third quarter worth approximately $320,000. Hedge funds and other institutional investors own 16.41% of the company’s stock.

Analysts Set New Price Targets

Several equities research analysts recently issued reports on the stock. StockNews.com upgraded shares of Cellectar Biosciences to a “sell” rating in a report on Thursday, March 28th. Roth Mkm raised their target price on shares of Cellectar Biosciences from $20.00 to $28.00 and gave the stock a “buy” rating in a report on Thursday, March 28th. Finally, Oppenheimer restated an “outperform” rating and issued a $12.00 target price (up previously from $11.00) on shares of Cellectar Biosciences in a report on Thursday, March 28th.

Cellectar Biosciences Price Performance

Shares of Cellectar Biosciences stock opened at $3.32 on Tuesday. The company’s fifty day simple moving average is $3.70 and its 200-day simple moving average is $3.09. The stock has a market capitalization of $107.11 million, a PE ratio of -1.07 and a beta of 0.92. Cellectar Biosciences, Inc. has a 1-year low of $1.33 and a 1-year high of $4.45.

Cellectar Biosciences Company Profile

Cellectar Biosciences, Inc, a clinical biopharmaceutical company, focuses on the discovery, development, and commercialization of drugs for the treatment of cancer. Its lead phospholipid drug conjugate (PDC) candidate is CLR 131 (iopofosine I-131), which is in Phase 2 clinical study for patients with B-cell malignancies; Phase 2a clinical study for patients with relapsed or refractory (r/r) Waldenstrom's macroglobulinemia cohort, r/r multiple myeloma (MM) cohort, and r/r non-Hodgkin's lymphoma cohort; Phase 1 clinical study for r/r pediatric patients with select solid tumors, lymphomas, and malignant brain tumors; and Phase 1 clinical study for r/r pediatric patients with head and neck cancer.